Roche: posts positive lung cancer drug data
(CercleFinance.com) - A Phase III study showed that Roche's Tecentriq and Avastin plus chemotherapy helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin and chemotherapy alone, the Swiss drugmaker said.
This analysis showed that the combination helped people with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, having a median overall survival of 19.2 months, versus 14.7 months for the other group.
Roche also said that follow-up phase III data showed Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death.
Alecensa more than tripled median progression-free survival (34.8 months compared to 10.9 months for Pfizer's crizotinib), the group said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This analysis showed that the combination helped people with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, having a median overall survival of 19.2 months, versus 14.7 months for the other group.
Roche also said that follow-up phase III data showed Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death.
Alecensa more than tripled median progression-free survival (34.8 months compared to 10.9 months for Pfizer's crizotinib), the group said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.